Biorestorative Therapies (BRTX)
(Real Time Quote from BATS)
$1.22 USD
-0.05 (-3.94%)
Updated Apr 25, 2024 10:40 AM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BRTX 1.22 -0.05(-3.94%)
Will BRTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRTX
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
BRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for BRTX
Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
BioRestorative's BRTX-100 trial to use sham injection control, says Roth MKM
BioRestorative gains as FDA clears amendment to study on cell therapy candidate
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
12 Health Care Stocks Moving In Tuesday's Pre-Market Session